8-KLeadership Changes

Cigna Group 8-K Report, Executive Changes (May 1, 2023)

Filed May 1, 2023For Securities:CI

Summary

The Cigna Group (CI) has filed an 8-K report detailing the appointment of Dr. Philip Ozuah as an independent member of its Board of Directors, effective June 1, 2023. Dr. Ozuah will also serve on the People Resources and Compliance Committees. This appointment is part of the company's ongoing governance practices and does not involve any disclosed related-party transactions or special compensation arrangements outside of the standard non-employee director compensation program. Investors should note that this is a routine governance update. The filing primarily serves to formally announce the addition of a new director to the board, contributing to the company's oversight and strategic guidance. The press release attached as an exhibit provides further details on the appointment.

Key Highlights

  • 1Dr. Philip Ozuah appointed as an independent director to The Cigna Group's Board of Directors.
  • 2Appointment is effective June 1, 2023.
  • 3Dr. Ozuah will also serve on the People Resources and Compliance Committees.
  • 4The appointment follows the company's standard non-employee director compensation program.
  • 5No related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.
  • 6Press release announcing the appointment is attached as an exhibit (Exhibit 99.1).

Frequently Asked Questions

Dr. Philip Ozuah has been appointed as an independent member of The Cigna Group's Board of Directors.

The appointment of Dr. Philip Ozuah is effective June 1, 2023.

Dr. Ozuah will serve on the People Resources and Compliance Committees of the Board.

No, Dr. Ozuah will participate in the Company’s non-employee director compensation program, as described in the company's Proxy Statement and its 2022 Form 10-K.

No, this 8-K filing is purely related to a change in board composition and does not provide information on the company's financial performance or operational changes.